- Home
- SRFM vs NKTX Comparison
SRFM vs NKTX Comparison
Compare SRFM & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRFM
- NKTX
- Stock Information
- Founded
- SRFM 2011
- NKTX 2015
- Country
- SRFM United States
- NKTX United States
- Employees
- SRFM N/A
- NKTX N/A
- Industry
- SRFM Transportation Services
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- SRFM Consumer Discretionary
- NKTX Health Care
- Exchange
- SRFM Nasdaq
- NKTX Nasdaq
- Market Cap
- SRFM 153.7M
- NKTX 147.7M
- IPO Year
- SRFM 2023
- NKTX 2020
- Fundamental
- Price
- SRFM $2.18
- NKTX $1.83
- Analyst Decision
- SRFM Buy
- NKTX Strong Buy
- Analyst Count
- SRFM 4
- NKTX 5
- Target Price
- SRFM $5.81
- NKTX $13.25
- AVG Volume (30 Days)
- SRFM 2.8M
- NKTX 698.2K
- Earning Date
- SRFM 11-12-2025
- NKTX 11-10-2025
- Dividend Yield
- SRFM N/A
- NKTX N/A
- EPS Growth
- SRFM N/A
- NKTX N/A
- EPS
- SRFM N/A
- NKTX N/A
- Revenue
- SRFM $108,158,000.00
- NKTX N/A
- Revenue This Year
- SRFM N/A
- NKTX N/A
- Revenue Next Year
- SRFM $18.06
- NKTX N/A
- P/E Ratio
- SRFM N/A
- NKTX N/A
- Revenue Growth
- SRFM N/A
- NKTX N/A
- 52 Week Low
- SRFM $1.77
- NKTX $1.31
- 52 Week High
- SRFM $9.91
- NKTX $3.16
- Technical
- Relative Strength Index (RSI)
- SRFM 25.57
- NKTX 40.43
- Support Level
- SRFM $1.99
- NKTX $1.77
- Resistance Level
- SRFM $2.12
- NKTX $1.83
- Average True Range (ATR)
- SRFM 0.26
- NKTX 0.09
- MACD
- SRFM -0.04
- NKTX -0.00
- Stochastic Oscillator
- SRFM 12.57
- NKTX 37.14
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.